Melissa B. Epperly, Chief Financial Officer at Zentalis Pharmaceuticals, Inc. (ZNTL), sold 26,858 shares at $50.76 ($1.4M) on 2020-12-04, disclosed to the SEC on 2020-12-08.
Open-market sale of $1.4M ZNTL by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.76 | 3,343 | $170K | 12.1% |
| 2 | $50.76 | 3,343 | $170K | 12.1% |
| 3 | $51.17 | 3,877 | $198K | 14.2% |
| 4 | $51.17 | 3,877 | $198K | 14.2% |
| 5 | $50.84 | 119 | $6K | 0.4% |
| 6 | $52.53 | 971 |
| $51K |
| 3.6% |
| 7 | $52.53 | 971 | $51K | 3.6% |
| 8 | $53.71 | 4,983 | $268K | 19.1% |
| 9 | $53.71 | 4,983 | $268K | 19.1% |
| 10 | $54.39 | 391 | $21K | 1.5% |
| Total | $52.15 avg | 26,858 | $1.4M | 100% |
| Filing → |
| ROIV | SELL | 2026-07-01 | $610K | — | Filing → |
| ROIV | SELL | 2026-03-18 | $1.2M | — | Filing → |
| ZNTL | SELL | 2024-02-12 | $29K | — | Filing → |